Bayer and Boehringer Ingelheim both had new data on their HER2-targeting small-molecule drugs to present at the World Conference on Lung Cancer (WCLC), hoping to add new oral therapies to the ...

The EMA has started a review of AstraZeneca and Daiichi Sankyo's antibody-drug conjugate (ADC) that could see the drug being used in advanced breast cancer with even lower levels of the HER2 ...

Dato-DXd significantly improved progression-free survival compared to chemotherapy in HR-positive, HER2-negative breast cancer patients. The study showed a 37% reduction in disease progression or ...

Itovebi is approved for PIK3CA-mutated, HR-positive, HER2-negative advanced breast cancer after adjuvant endocrine therapy recurrence. The INAVO120 trial showed Itovebi improved progression-free ...